BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: El Hindi S, Reiser J. TRPC channel modulation in podocytes-inching toward novel treatments for glomerular disease. Pediatr Nephrol 2011;26:1057-64. [PMID: 21161284 DOI: 10.1007/s00467-010-1718-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
Number Citing Articles
1 Mottl AK, Lu M, Fine CA, Weck KE. A novel TRPC6 mutation in a family with podocytopathy and clinical variability. BMC Nephrol 2013;14:104. [PMID: 23663351 DOI: 10.1186/1471-2369-14-104] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
2 Hall G, Wang L, Spurney RF. TRPC Channels in Proteinuric Kidney Diseases. Cells 2019;9:E44. [PMID: 31877991 DOI: 10.3390/cells9010044] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
3 Urban N, Neuser S, Hentschel A, Köhling S, Rademann J, Schaefer M. Pharmacological inhibition of focal segmental glomerulosclerosis-related, gain of function mutants of TRPC6 channels by semi-synthetic derivatives of larixol. Br J Pharmacol 2017;174:4099-122. [PMID: 28800680 DOI: 10.1111/bph.13977] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
4 Liu X, Zhang T, Xia W, Wang Y, Ma K. Recombinant human erythropoietin pretreatment alleviates renal glomerular injury induced by cardiopulmonary bypass by reducing transient receptor potential channel 6-nuclear factor of activated T-cells pathway activation. J Thorac Cardiovasc Surg 2013;146:681-7. [PMID: 23535151 DOI: 10.1016/j.jtcvs.2013.02.076] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
5 Wang L, Jirka G, Rosenberg PB, Buckley AF, Gomez JA, Fields TA, Winn MP, Spurney RF. Gq signaling causes glomerular injury by activating TRPC6. J Clin Invest 2015;125:1913-26. [PMID: 25844902 DOI: 10.1172/JCI76767] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 5.7] [Reference Citation Analysis]
6 Nilius B, Szallasi A, Sibley DR. Transient Receptor Potential Channels as Drug Targets: From the Science of Basic Research to the Art of Medicine. Pharmacol Rev 2014;66:676-814. [DOI: 10.1124/pr.113.008268] [Cited by in Crossref: 291] [Cited by in F6Publishing: 274] [Article Influence: 36.4] [Reference Citation Analysis]
7 Shen S, Jin Y, Li W, Liu X, Zhang T, Xia W, Wang Y, Ma K. Recombinant human erythropoietin pretreatment attenuates acute renal tubular injury against ischemia-reperfusion by restoring transient receptor potential channel-6 expression and function in collecting ducts. Crit Care Med 2014;42:e663-72. [PMID: 25072760 DOI: 10.1097/CCM.0000000000000542] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
8 Forst AL, Olteanu VS, Mollet G, Wlodkowski T, Schaefer F, Dietrich A, Reiser J, Gudermann T, Mederos y Schnitzler M, Storch U. Podocyte Purinergic P2X4 Channels Are Mechanotransducers That Mediate Cytoskeletal Disorganization. J Am Soc Nephrol 2016;27:848-62. [PMID: 26160898 DOI: 10.1681/ASN.2014111144] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
9 Swiatecka-Urban A. Membrane trafficking in podocyte health and disease. Pediatr Nephrol 2013;28:1723-37. [PMID: 22932996 DOI: 10.1007/s00467-012-2281-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
10 Hu G, He Y, Li Y, Hu X, Liu S, Liao C, Zhang R, Zhou X, Sun H. Effect of HIF1α on the TRPC6 channel of glomerular podocytes under chronic hypoxia. Biochem Biophys Res Commun 2021;541:1-7. [PMID: 33450580 DOI: 10.1016/j.bbrc.2020.12.088] [Reference Citation Analysis]